Clinical trialNCT06929286RecruitingPhase 3Interventional

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

SponsorMemorial Sloan Kettering Cancer CenterEnrollment125Non-Muscle Invasive Bladder Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to compare the effectiveness of different FDA-approved/NCCN-recommended drug treatments for NMIBC. In particular, the FDA-approved drug nadofaragene firadenovec will be compared to usual care with other NCCN-recommended standard treatments for NMIBC (gemcitabine with or without docetaxel, mitomycin, re-treatment with BCG, or pembrolizumab).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eugene Pietzak, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Johns Hopkins University (data Collection Only)
Baltimore, Maryland, United States
Not, yet, recruiting
Memorial Sloan Kettering Basking Ridge (consent Only)
Basking Ridge, New Jersey, United States
Recruiting
Memorial Sloan Kettering Monmouth (consent Only)
Middletown, New Jersey, United States
Recruiting
Memorial Sloan Kettering Bergen (consent Only)
Montvale, New Jersey, United States
Recruiting
Memorial Sloan Kettering Suffolk - Commack (consent Only)
Commack, New York, United States
Recruiting
Memorial Sloan Kettering Westchester (consent Only)
East White Plains, New York, United States
Recruiting
Columbia University (data Collection Only)
New York, New York, United States
Not, yet, recruiting
Memorial Sloan Kettering Cancer Center (all Protocol Activities)
New York, New York, United States
Eugene Pietzak, MD
Recruiting
Memorial Sloan Kettering Nassau (consent Only)
Uniondale, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Docetaxel →Gemcitabine →Nadofaragene firadenovec

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Apr 2025
Primary completion: 30 Apr 2028
Completion: 30 Apr 2028
Last update posted: 20 Aug 2026
Registered enrollment: 125
Registry id: NCT06929286

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.